갑상선암 세포주에서 Troglitazone의 분화 유도 효과
Redifferentiation Effects of Troglitazone in Human Thyroid Cancer Cell Lines
박종찬, 류동희, Orlo H. Clark,
소속 상세정보
박종찬 ( Park Jong-Chan )
Chungbuk National University
류동희 ( Ryu Dong-Hee )
청주성모병원 외과
( Orlo H. Clark )
Department of Surgery University of California San Francisco
KMID : 0371320040670020093
Abstract
PURPOSE: Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma), which is a ligand-activated transcription factor that regulates cell differentiation and growth. Antiproliferative effects of troglitazone have been reported in several human cancers including thyroid cancer. In the present study, we evaluated the redifferentiation effects of troglitazone in human cancers regarding the modulation of CD97 and sodium-iodide symporter (NIS) gene expression.
METHODS: We used 3 human thyroid cancer cell lines: TPC-1 (papillary), FTC-133 (follicular), and XTC-1 (H rthle). Surface expression of CD97, a novel dedifferentiation marker, was measured by flow cytometry. mRNA expression of NIS gene was measured by real time quantitative PCR using TaqMan probe.
RESULTS: Troglitazone down-regulated the surface expression of CD97 in FTC-133 cells and up-regulated (NIS) mRNA in TPC-1, FTC-133 and XTC-1 cells.
CONCLUSION: Our investigations documented that troglitazone, a PPARgammaagonist, induced redifferentiation in thyroid cancer cell lines. In patients who have poorly differentiated thyroid cancer unresponsive to traditional treatments, PPARgammaagonists may therefore reintroduce the effectiveness of traditional treatments.
키워드
재분화;Peroxisome proliferator-activated receptors;PPAR;Redifferentiation;CD97;Sodium-iodide symporter
원문 및 링크아웃 정보
등재저널 정보